German drug maker Boehringer-Ingelheim and Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co., Ltd. declared strategic cooperative agreement to build up the first Chinese biopharmaceutical base using mammal cell culture technology for production under multinationals.
The biopharmaceutical base will be engaged in technology development and international GMP production, planning to lure more than EUR 35 million from Boehringer-Ingelheim and be put into operation in early 2016, when all dimensional service from research and development to clinical tests will be offered to customers home and abroad.
A top executive from the China region of Boehringer-Ingelheim in charge of GMP biomedicine supply said that the biopharmaceutical base will start international GMP production in 2016, with output value reaching hundreds of millions in the early stage and production capacity able to be tripled or even quadrupled shortly according to market demands.
